Close menu




August 2nd, 2022 | 10:57 CEST

Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies

  • Expert
  • Biotech
  • Cancer
  • DefenceTherapeutics
Photo credits: pixabay.com

The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.

time to read: 1 minutes | Author: Mario Hose
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Bill Radvak, CEO, NervGen Pharma
    "[...] In summary, there are many different healing processes that make us very confident that our drug has the ability to help many millions of people with a wide variety of causes of nervous system damage. [...]" Bill Radvak, CEO, NervGen Pharma

    Full interview

     

    Cancer is one of the most common causes of death and those affected often have a long journey of suffering. What progress can Defence Therapeutics show in the field of fighting the disease?

    'Cancer is a multifactorial disease caused by mutations accumulated through years. Therefore, targeting cancer through a specific pathway may not lead to the hoped-for outcome.

    Defence is working on the development of the next generation oncology-targeting therapies. Most of its arsenal is based on the use of the Accum technology, which consists of empowering biomedicine's accumulation into target cells via endosomal escape.

    As such, the company has developed antibody-drug conjugates, anti-cancer small molecules and protein- or cell-based anti-cancer vaccine formulations. Multiple Phase I trials using some of these products are expected to start in Q1/Q2 of 2023.'

    Dr. Moutih Rafei, VP Research & Development, Defence Therapeutics Inc.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on April 25th, 2025 | 07:20 CEST

    US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma

    The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

    Read

    Commented by Fabian Lorenz on April 25th, 2025 | 07:00 CEST

    RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?

    • Biotechnology
    • Biotech
    • Defense

    Is RENK on the verge of a takeover? In any case, the antitrust authorities have approved the entry of a new major shareholder. Could the takeover of the gearbox manufacturer herald a consolidation in the European defense industry, as announced by the head of Hensoldt? So far, there have only been small acquisitions, such as those of Rheinmetall. There is also movement in the pharmaceutical and biotech sectors. The Trump tariffs are shaking up the industry. NetraMark's AI software helps reduce costs and save time in drug research. The AI insider tip's stock still appears cheap and could skyrocket amid takeover speculation. Evotec has also been repeatedly mentioned as a takeover candidate. Yesterday, a large milestone payment was reported. How are the shares performing?

    Read

    Commented by André Will-Laudien on April 22nd, 2025 | 07:20 CEST

    This is the post-Easter opportunity! Evotec, Bayer, BioNTech, and Defence Therapeutics in focus

    • Biotechnology
    • Biotech
    • Pharma

    Donald Trump snubs his international partners, insults prominent Americans, and withdraws long-standing funding commitments to Harvard. Who would have thought? The new US administration is turning out to be an unpredictable fragmentation bomb that could hit anyone. Economic policy resembles a game of hot and cold when stability is needed. On the stock market, investors are trying to price in old tariffs, no tariffs, and new tariffs - every day brings a fresh bouquet of announced measures. There has hardly been a similarly volatile period in recent years, but Donald Trump is not interested in stock market prices. For the overvalued high-tech sector, this is a welcome opportunity to take profits. The biotech sector could finally take off were it not for the sharp rise in interest rates. The only thing that can help now is a case-by-case assessment of investment opportunities.

    Read